{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:43:42Z","timestamp":1760183022480,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.rdc.2015.08.011","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T04:42:09Z","timestamp":1445920929000},"page":"103-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Corticosteroids in Myositis and Scleroderma"],"prefix":"10.1016","volume":"42","author":[{"given":"Anna","family":"Postolova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2015.08.011_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mayocp.2012.10.017","article-title":"Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations","volume":"88","author":"Ernste","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2015.08.011_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","article-title":"Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis","volume":"7","author":"Mammen","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.011_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.rdc.2015.08.011_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":"A\u00a0computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"86","author":"Bohan","year":"1977","journal-title":"Medicine"},{"key":"10.1016\/j.rdc.2015.08.011_bib5","unstructured":"Tjarnlund A, Bottai M, Rider LG, et\u00a0al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Washington, DC: ACR Annual Meeting. 2012. Abstract."},{"key":"10.1016\/j.rdc.2015.08.011_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.rdc.2015.08.011_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","article-title":"Cutaneous dermatomyositis: an updated review of treatment options and internal associations","volume":"14","author":"Femia","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/09546634.2012.697540","article-title":"Review of dermatomyositis: establishing the diagnosis and treatment algorithm","volume":"24","author":"Strowd","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.rdc.2015.08.011_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rdc.2014.12.006","article-title":"Pulmonary complications of inflammatory myopathy","volume":"41","author":"Miller","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2015.08.011_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/01.bor.0000434664.37880.ac","article-title":"The diagnostic utility of autoantibodies in adult and juvenile myositis","volume":"25","author":"Tansley","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/08916930410001710839","article-title":"Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies","volume":"37","author":"Sarkar","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.rdc.2015.08.011_bib12","first-page":"545","article-title":"Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients","volume":"43","author":"Winkelmann","year":"1968","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2015.08.011_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V","article-title":"Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis","volume":"43","author":"Lundberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2015.08.011_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","article-title":"Amyopathic dermatomyositis (dermatomyositis sine myositis) presentation of six new cases and review of the literature","volume":"24","author":"Euwer","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotype","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.rdc.2015.08.011_bib18","article-title":"Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review","author":"Gil","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0190-9622(96)90037-7","article-title":"Guidelines of care for dermatomyositis. American Academy Dermatology","volume":"34","author":"Drake","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2015.08.011_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/1744666X.2013.842467","article-title":"Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives","volume":"9","author":"Schmidt","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.rdc.2015.08.011_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rdc.2015.08.011_bib24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp.2009.173823","article-title":"Inclusion body myositis: old and new concepts","volume":"80","author":"Amato","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.rdc.2015.08.011_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11926-013-0329-z","article-title":"Update on treatment of inclusion body myositis","volume":"15","author":"Breithaupt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2015.08.011_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CND.0000000000000065","article-title":"Necrotizing myopathies: an update","volume":"16","author":"Quinn","year":"2015","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.rdc.2015.08.011_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2015.08.011_bib28","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A\u00a0novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.rdc.2015.08.011_bib30","first-page":"S194","article-title":"Systemic sclerosis: a critical digest of the recent literature","volume":"32","author":"Barsotti","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11926-011-0220-8","article-title":"Scleroderma mimics","volume":"14","author":"Nashel","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2015.08.011_bib32","first-page":"167","article-title":"Autoantibodies in systemic sclerosis: unanswered questions","volume":"15","author":"Kayser","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2015.08.011_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2010.05.045","article-title":"Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis","volume":"64","author":"Fett","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2013.01.010","article-title":"Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies","volume":"31","author":"Fett","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","article-title":"Pediatric morphea (localized scleroderma): review of 136 patients","volume":"59","author":"Christen-Zaech","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1346-8138.2002.tb00301.x","article-title":"Unilateral generalized morphea in childhood","volume":"29","author":"Nagai","year":"2002","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2133.2007.07971.x","article-title":"First case series on the use of calcipotriol-betamethasone dipropionate for morphoea","volume":"157","author":"Dytoc","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/jnnp.74.5.661","article-title":"Linear scleroderma \u201cen coup de sabre\u201d coexisting with plaque-morphea: neuroradiological manifestation and response to corticosteroids","volume":"74","author":"Unterberger","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.rdc.2015.08.011_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","article-title":"A\u00a0systematic review of morphea treatments and therapeutic algorithm","volume":"65","author":"Zwischenberger","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib41","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.110210","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study","volume":"39","author":"Torok","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","article-title":"Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients","volume":"130","author":"Joly","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaad.2010.05.046","article-title":"Update on morphea: part II. Outcome measures and treatment","volume":"64","author":"Fett","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausbol-Gron","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.rdc.2015.08.011_bib46","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib47","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G","article-title":"Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients","volume":"43","author":"Poormoghim","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.011_bib48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research Group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.011_bib49","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2015.08.011_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.mayocp.2013.01.018","article-title":"My approach to the treatment of scleroderma","volume":"88","author":"Shah","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2015.08.011_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2012.191","article-title":"Systemic sclerosis\u2014challenges for clinical practice","volume":"9","author":"McMahan","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.011_bib52","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","article-title":"Kidney involvement in systemic sclerosis","volume":"43","author":"Steen","year":"2014","journal-title":"Presse Med"},{"key":"10.1016\/j.rdc.2015.08.011_bib53","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2634","article-title":"High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy","volume":"11","author":"Hunzelmann","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2015.08.011_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0034-1371541","article-title":"Interstitial lung disease in systemic sclerosis","volume":"35","author":"Wells","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2015.08.011_bib55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.rdc.2014.12.005","article-title":"Interstitial lung disease in scleroderma","volume":"41","author":"Schoenfeld","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2015.08.011_bib56","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:15:02Z","timestamp":1760181302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X15000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889857X15000757"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.011","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids in Myositis and Scleroderma","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}